title: Antiapoptotic actions of exendin-4 against hypoxia and cytokines are augmented by CREB.
abstract: Islets isolated from cadaveric donor pancreas are functionally viable and can be transplanted in diabetic patients to reduce insulin requirements. This therapeutic approach is less efficient because a significant portion of functional islets is lost due to oxidative stress, inflammation, and hypoxia. Exendin-4, a glucagon-like peptide-1 receptor agonist, is known to improve islet survival through activation of the transcription factor, cAMP response element binding protein (CREB). However, isolated human islets are exposed to several stresses known to down-regulate CREB. The objective of the present study was to determine whether the cytoprotective actions of exendin-4 in human islets can be augmented by increasing the levels of CREB. Simulation of ischemia/reperfusion injury and exposure to hypoxic conditions in cultured human islets resulted in decreased CREB activation and induction of apoptosis. Islets were transduced with adenoviral CREB followed by exposure to exendin-4 as a strategy for improving their survival. This combination increased the levels of several proteins needed for β-cell survival and function, including insulin receptor substrate-2, Bcl-2, and baculoviral IAP repeat-containing 3, and suppressed the expression of proapoptotic and inflammatory genes. A combination of CREB and exendin-4 exerted enhanced antiapoptotic action in cultured islets against hypoxia and cytokines. More significantly, transplantation of human islets transduced with adenoviral CREB and treated with exendin-4 showed improved glycemic control over a 30-d period in diabetic athymic nude mice. These observations have significant implications in the therapeutic potential of exendin-4 and CREB in the islet transplantation setting as well as in preserving β-cell mass of diabetic patients.
authors.affiliation: Section of Endocrinology, Veterans Affairs Medical Center, Denver, Colorado 80220, USA.
authors.forename: Kalpana
authors.initials: K
authors.lastname: Velmurugan
authors.forename: A N
authors.initials: AN
authors.lastname: Balamurugan
authors.forename: Gopalakrishnan
authors.initials: G
authors.lastname: Loganathan
authors.forename: Aftab
authors.initials: A
authors.lastname: Ahmad
authors.forename: Bernhard J
authors.initials: BJ
authors.lastname: Hering
authors.forename: Subbiah
authors.initials: S
authors.lastname: Pugazhenthi
mesh_terms: D000818:Animals; D017209:Apoptosis; D002460:Cell Line; D002478:Cells, Cultured; D003198:Computer Simulation; D017362:Cyclic AMP Response Element-Binding Protein / Q000378:metabolism*; D016207:Cytokines / Q000378:metabolism*; D000077270:Exenatide; D006801:Humans; D000860:Hypoxia; D055504:Insulin Receptor Substrate Proteins / Q000378:metabolism; D050417:Insulin-Secreting Cells / Q000166:cytology; D007515:Islets of Langerhans / Q000166:cytology; D008297:Male; D051379:Mice; D008819:Mice, Nude; D010179:Pancreas / Q000378:metabolism; D010455:Peptides / Q000494:pharmacology*; D015427:Reperfusion Injury / Q000473:pathology; D015398:Signal Transduction; D014688:Venoms / Q000494:pharmacology*
chemical_list: C115163:CREB1 protein, human; C492004:Creb1 protein, mouse; D017362:Cyclic AMP Response Element-Binding Protein; D016207:Cytokines; D055504:Insulin Receptor Substrate Proteins; D010455:Peptides; D014688:Venoms; D000077270:Exenatide